Table II.

Adverse events associated with Dur/Tre (n=120).

Adverse event	Any, n (%)	Grade 3 or higher, n (%)
Total adverse events	100 (83.3)	44 (36.7)
AST evaluation	61 (50.8)	16 (13.3)
ALT evaluation	45 (37.5)	13 (10.8)
Rash	45 (37.5)	10 (8.3)
Fever	27 (22.5)	1 (0.8)
Diarrhea	22 (18.3)	12 (10.0)
Abdominal pain	8 (6.7)	2 (1.6)
Pituitary or adrenal insufficiency	6 (5.0)	6 (5.0)
Drug-induced pneumonia	6 (5.0)	4 (3.3)
Pancreatitis	3 (2.4)	2 (1.6)
Infusion reaction	4 (3.3)	1 (0.8)
Other irAEs	8 (6.7)	4 (3.3)
Fatigue	26 (21.6)	5 (4.1)
Decreased appetite	29 (24.1)	1 (0.8)
Factors
Requiring high-dose steroid		27 (22.5)

Dur/Tre, durvalumab plus tremelimumab; AST, aspartate aminotransferase; ALT, alanine aminotransferase; irAEs, immune-related adverse events.